We grouped patients according to the FGF21 status, and in MASLD patients with increased FGF21 expression 65% were MASH cases as compared with 73.6% in patients with decreased FGF21 expression. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.